Altimmune, Inc.

ALT

US02155H2004

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2026-01-20 EST			5-day change	1st Jan Change
4.230 ^USD	-0.24%		+5.49%	+17.17%

01-05	Altimmune, Inc. Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH	CI
01-05	Altimmune Says US FDA Grants Breakthrough Therapy Designation for Pemvidutide in MASH	MT

Altimmune's weight-loss drug meets main goal in fatty liver disease trial

Published on 06/26/2025 at 07:26 am EDT

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Altimmune, Inc.

01-05	Altimmune, Inc. Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH	CI
01-05	Altimmune Says US FDA Grants Breakthrough Therapy Designation for Pemvidutide in MASH	MT
01-05	Altimmune receives FDA breakthrough therapy designation for pemvidutide in mash	RE
12-23	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE
12-19	Altimmune, Inc. - Special Call
12-19	Altimmune, Inc. Announces Positive Topline Results from the Impact Phase 2B Mash Trial	CI
12-19	Altimmune Says Pemvidutide Showed "Significant" Improvements in MASH Patients at 48 Weeks	MT
12-19	Altimmune's liver disease drug shows benefits in study, but investors remain unimpressed	RE
12-19	Altimmune's drug for a type of liver disease shows benefits in mid-stage study	RE
12-19	Altimmune shares climb 6.9% premarket after positive trial data	RE
12-12	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE
12-08	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE
12-01	Altimmune, Inc. Announces CEO Changes	CI
12-01	Altimmune, Inc. Announces Executive Changes	CI
12-01	Altimmune CEO Vipin Garg to Step Down	MT
12-01	Altimmune announces CEO transition, succession plan	RE
11-25	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE
11-20	Altimmune, Inc. Presents at Jefferies London Healthcare Conference 2025, Nov-20-2025 08:00 AM
11-11	Altimmune, Inc. Announces Publication of Impact Phase 2B Trial Data in the Lancet and Concurrent Late-Breaking Oral Presentation At Aasld the Liver Meeting®? 2025	CI
11-10	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE
11-10	Celldex Therapeutics, Inc. Announces Executive Changes	CI
11-07	Altimmune, Inc. Presents Ai-Based Analysis of Liver Fibrosis Reduction from Impact Phase 2B Trial of Pemvidutide Inash in Late-Breaking Poster At Aasld the Liver Meeting®? 2025	CI
11-06	Altimmune Inc files for mixed shelf of up to $400 million - SEC filing	RE
11-06	Altimmune files for offering of common stock of up to $200 million - filing	RE
11-06	Altimmune, Inc., Q3 2025 Earnings Call, Nov 06, 2025

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. The Company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. It is also developing HepTcell, an immunotherapeutic product candidate for patients chronically infected with the hepatitis B virus (HBV). The Company has completed the enrollment in its Phase II clinical trial of HepTcell. Its product candidates are based on its proprietary platform technologies, such as EuPort-based Peptide Technology and Synthetic Peptide Technology-Densigen. The Companyâs wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.

Employees

Sector

Biotechnology & Medical Research

Calendar

03-25 - Q4 2025 Earnings Release (Projected)

More about the company